DAFTAR PUSTAKA

Akman, B. H., Can, T., Elif Erson-Bensan, A., & Bensan, E. E. (2012). Estrogen-induced upregulation and 3′-UTR shortening of CDC6. *Nucleic Acids Research*, *40*(21), 10679–10688. https://doi.org/10.1093/nar/gks855

Al-eitan, L. N., Rababa, D. M., Alghamdi, M. A., & Khasawneh, R. H. (2019). *breast Cancer in Jordan : a case-control study*. *1*, 1–10.

Aldeman, N. L. S., Palhares, D. M. F., Araíjo, S. A., Pedrosa, M. S., Castro, L. L., Arantes, V. N., & Cabral, M. M. D. Á. (2013). The role of immunohistochemistry in the detection of vascular invasion in specimens of endoscopic submucosal dissection. *Jornal Brasileiro de Patologia e Medicina Laboratorial*, *49*(4), 273–277. https://doi.org/10.1590/S1676-24442013000400008

Ali, S., & Coombes, R. C. (2000). Estrogen receptor alpha in human breast cancer: Occurrence and significance. *Journal of Mammary Gland Biology and Neoplasia*, Vol. 5, pp. 271–281. https://doi.org/10.1023/A:1009594727358

Allison, K. H. (2012). Molecular pathology of breast cancer: What a pathologist needs to know. *American Journal of Clinical Pathology*, *138*(6), 770–780. https://doi.org/10.1309/AJCPIV9IQ1MRQMOO

American Cancer Society. (2017). *About Breast Cancer*. 1–19.

American Cancer Society. (2017). *Breast Cancer Facts & Figure 2017-2018*. 2–3.

Anghel, A, Raica, M., Narita, D., Seclaman, E., Nicola, T., Ursoniu, S. et al., (2010). Estrogen receptor alpha polymorphisms: correlation with clinicopathological parameters in breast cancer. *Neoplasma*, *57*(4), 306–315. https://doi.org/10.4149/neo

Anghel, Andrei, Narita, D., Seclaman, E., Popovici, E., Anghel, M., & Tamas, L. (2010). Estrogen receptor alpha polymorphisms and the risk of malignancies. *Pathology and Oncology Research*, *16*(4), 485–496. https://doi.org/10.1007/s12253-010-9263-9

Babyshkina, N., Vtorushin, S., Zavyalova, M., Patalyak, S., Dronova, T., Litviakov, N. et al., (2017). The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen. *Clinical and Experimental Medicine*, *17*(3), 383–393. https://doi.org/10.1007/s10238-016-0428-z

Bashirullah, A., Cooperstock, R. L., Lipshitz, H. D., & Lipshitz, H. (2001). Spatial and temporal control of RNA stability. *Proceedings of the National Academy of Sciences of the United States of America*, *98*(13), 7025–7028. https://doi.org/10.1073/pnas.111145698

Basse, C., & Arock, M. (2015). The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment. *International Journal of Cancer*, *137*(12), 2785–2794. https://doi.org/10.1002/ijc.29347

Bradley, K. T. (n.d.). Prognostic and predictive. *Clinical Oncology*.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, *68*(6), 394–424. https://doi.org/10.3322/caac.21492

Britto, A. V., Schenka, A. A., Moraes-Schenka, N. G., Alvarenga, M., Shinzato, J. Y., Vassallo, J., & Ward, L. S. (2009). Immunostaining with D2-40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancer. *BMC Cancer*, *9*, 1–8. https://doi.org/10.1186/1471-2407-9-109

Brown, D. C., & Gatter, K. C. (2002). Ki67 protein: The immaculate deception? *Histopathology*, *40*(1), 2–11. https://doi.org/10.1046/j.1365-2559.2002.01343.x

Bukhari, M. H. (2011). New molecular aspect of breast carcinoma: Its diagnosis, treatment and prognosis. *Clinical Biochemistry*, *44*(13), S210–S211. https://doi.org/10.1016/j.clinbiochem.2011.08.523

Bustreo, S., Osella-Abate, S., Cassoni, P., Donadio, M., Airoldi, M., Pedani, F. et al., (2016). Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. *Breast Cancer Research and Treatment*, *157*(2), 363–371. https://doi.org/10.1007/s10549-016-3817-9

Carausu, M., Bidard, F. C., Callens, C., Melaabi, S., Jeannot, E., Pierga, J. Y., & Cabel, L. (2019). ESR1 mutations: a new biomarker in breast cancer. *Expert Review of Molecular Diagnostics*, *19*(7), 599–611. https://doi.org/10.1080/14737159.2019.1631799

Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J. et al., (2009). Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *Journal of the National Cancer Institute*, *101*(10), 736–750. https://doi.org/10.1093/jnci/djp082

Clemons, M., & Goss, P. (2001). Estrogen and The Risk of Breast Cancer. *English Journal*, *344*(4), 276–285. https://doi.org/10.1634/theoncologist.11-5-435

Clusan, L., Goff, P. Le, Flouriot, G., & Pakdel, F. (2021). A closer look at estrogen receptor mutations in breast cancer and their implications for estrogen and antiestrogen responses. *International Journal of Molecular Sciences*, *22*(2), 1–16. https://doi.org/10.3390/ijms22020756

Dai, Z., Tian, T., Wang, M., Yang, T., Li, H., Lin, S. et al., (2019). Genetic polymorphisms of estrogen receptor genes are associated with breast cancer susceptibility in Chinese women 11 Medical and Health Sciences 1112

Oncology and Carcinogenesis. *Cancer Cell International*, *19*(1), 1–7. https://doi.org/10.1186/s12935-019-0727-z

Dehkordi, Parsafar, Ghaedi, & Peymani. (2018). rs3798577 polymorphism located in a putative miRNAs target site of estrogen receptor 1 reduced breast cancer risk in an Iranian population. *European Journal of Oncology*, *23*(2), 103–108.

Ding, S. L., Yu, J. C., Chen, S. T., Hsu, G. C., Hsu, H. M., Ho, J. Y. et al., (2010). Diverse associations between ESR1 polymorphism and breast cancer development and progression. *Clinical Cancer Research*, *16*(13), 3473–3484. https://doi.org/10.1158/1078-0432.CCR-09-3092

Dunning, A. M., Healey, C. S., Pharoah, P. D. P., Teare, M. D., Ponder, B. A. J., & Easton, D. F. (1999). A systematic review of genetic polymorphisms and breast cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, *8*(10), 843–854.

Dunning, A. M., Michailidou, K., Kuchenbaecker, K. B., Thompson, D., French, J. D., Beesley, J. et al., (2016). Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170 A. *Nat Genet*, *48*(4), 374–386. https://doi.org/doi:10.1038/ng.3521

Falck, A. K., Fernö, M., Bendahl, P. O., & Rydén, L. (2013). St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: Results from a prospective randomised trial. *BMC Cancer*, *13*, 1–10. https://doi.org/10.1186/1471-2407-13-558

Fasching, P. A., Pharoah, P. D. P., Cox, A., Nevanlinna, H., Bojesen, S. E., Karn, T. et al., (2012). The role of genetic breast cancer susceptibility variants as prognostic factors. *Human Molecular Genetics*, *21*(17), 3926–3939. https://doi.org/10.1093/hmg/dds159

Fuentes, N., & Silveyra, P. (2019). Estrogen receptor signaling mechanisms. *Advances in Protein Chemistry and Structural Biology*, *116*(March), 135–170. https://doi.org/10.1016/bs.apcsb.2019.01.001

Germain, D. (2011). Estrogen Carcinogenesis in Breast Cancer. *Endocrinology and Metabolism Clinics of North America*, *40*(3), 473–484. https://doi.org/10.1016/j.ecl.2011.05.009

Ghali, R. M., Al-Mutawa, M. A., Al-Ansari, A. K., Zaied, S., Bhiri, H., Mahjoub, T., & Almawi, W. Y. (2018). Differential association of ESR1 and ESR2 gene variants with the risk of breast cancer and associated features: A case-control study. *Gene*, *651*(February), 194–199. https://doi.org/10.1016/j.gene.2018.02.011

Gold, B., Kalush, F., Bergeron, J., Scott, K., Mitra, N., Wilson, K. at al., (2004). Estrogen receptor genotypes and haplotypes associated with breast cancer risk. *Cancer Research*, *64*(24), 8891–8900. https://doi.org/10.1158/0008-5472.CAN-04-1256

Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H. J. (2011). Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. *Annals of Oncology*, *22*(8), 1736–1747. https://doi.org/10.1093/annonc/mdr304

Gu, Y., Chen, T., López, E., Wu, W., Wang, X., Cao, J., & Teng, L. (2014). The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors. *Journal of Translational Medicine*, *12*(1), 1–12. https://doi.org/10.1186/1479-5876-12-16

Haff, L. A., & Smirnov, I. P. (1997). Single-nucleotide polymorphism identification assays using a thermostable DNA polymerase and delayed extraction MALDI-TOF mass spectrometry. *Genome Research*, *7*(4), 378–388. https://doi.org/10.1101/gr.7.4.378

Hammes, S. R., & Levin, E. R. (2019). Impact of estrogens in males and androgens in females. *Journal of Clinical Investigation*, *129*(5), 1818–1826. https://doi.org/10.1172/JCI125755

Han, J., Jiang, T., Bai, H., Gu, H., Dong, J., Ma, H. et al., (2011). Genetic variants of 6q25 and breast cancer susceptibility: A two-stage fine mapping study in a Chinese population. *Breast Cancer Research and Treatment*, *129*(3), 901–907. https://doi.org/10.1007/s10549-011-1527-x

Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. *Cancer Discovery*, *12*(1), 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. *Cell*, *144*(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013

Harahap, W., Khambri, D., Nindrea, R., & Yetti, H. (2019). *Breast Cancer Immunohistochemistry Features Among Young Women in West Sumatera, Indonesia*. 1–8. https://doi.org/10.4108/eai.13-11-2018.2283689

Hashemi, R., Arefhosseini, S. R., Folkerts, G., Varasteh, S., & Morshedi, M. (2020). Targeted nutrigenomics as a means of breast cancer management: from DNA methylation to microRNAs. *Integrative Food, Nutrition and Metabolism*, *7*(3), 1–14. https://doi.org/10.15761/ifnm.1000288

Hertz, D. L., Henry, N. L., Kidwell, K. M., Thomas, D., Goddard, A., Azzouz, F. et al., (2016). ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. *Physiological Genomics*, *48*(9), 688–698. https://doi.org/10.1152/physiolgenomics.00065.2016

Ingolf, J. B., Russalina, M., Simona, M., Julia, R., Gilda, S., Bohle, R. M. et al., (2014). Can Ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy? *BioMed Research International*, *2014*. https://doi.org/10.1155/2014/628217

Inwald, E. C., Klinkhammer-Schalke, M., Hofstädter, F., Zeman, F., Koller, M., Gerstenhauer, M., & Ortmann, O. (2013). Ki-67 is a prognostic parameter in breast cancer patients: Results of a large population-based cohort of a cancer registry. *Breast Cancer Research and Treatment*, *139*(2), 539–552. https://doi.org/10.1007/s10549-013-2560-8

Ireka, Y., Agustina, H., Aziz, A., Hernowo, B. S., & Suryanti, S. (2019). Comparison of fixation methods for preservation cytology specimens of cell block preparation using 10% neutral buffer formalin and 96% alcohol fixation in E-cadherin and Ki-67 immunohistochemical examination. *Open Access Macedonian Journal of Medical Sciences*, *7*(19), 3139–3144. https://doi.org/10.3889/oamjms.2019.452

Jansen, R. P. (2001). mRNA localization: Message on the move. *Nature Reviews Molecular Cell Biology*, *2*(4), 247–256. https://doi.org/10.1038/35067016

Jensen, K., Krusenstjerna-Hafstrøm, R., Lohse, J., Petersen, K. H., & Derand, H. (2017). A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: Analytical performance measuring HER2. *Modern Pathology*, *30*(2), 180–193. https://doi.org/10.1038/modpathol.2016.176

Jeon, T., Kim, A., & Kim, C. (2021). Automated immunohistochemical assessment ability to evaluate estrogen and progesterone receptor status compared with quantitative reverse transcription-polymerase chain reaction in breast carcinoma patients. *Journal of Pathology and Translational Medicine*, *55*(1), 33–42. https://doi.org/10.4132/JPTM.2020.09.29

Joensuu, K., Leidenius, M., Kero, M., Andersson, L. C., Horwitz, K. B., & Heikkilä, P. (2013). ER, PR, HER2, Ki-67 and CK5 in early and late relapsing breast cancer-reduced CK5 expression in metastases. *Breast Cancer: Basic and Clinical Research*, *7*(1), 23–34. https://doi.org/10.4137/BCBCR.S10701

Kamińska, M., Ciszewski, T., Łopacka-Szatan, K., Miotła, P., & Starosławska, E. (2015). Breast cancer risk factors. *Przeglad Menopauzalny*, *14*(3), 196–202. https://doi.org/10.5114/pm.2015.54346

Kao, J., Salari, K., Bocanegra, M., Choi, Y. La, Girard, L., Gandhi, J. et al., (2009). Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. *PLoS ONE*, *4*(7). https://doi.org/10.1371/journal.pone.0006146

Kariri, Y. A., Aleskandarany, M. A., Joseph, C., Kurozumi, S., Mohammed, O. J., Toss, M. S. et al., (2020). Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype. *Pathobiology*, *87*(4), 218–231. https://doi.org/10.1159/000508337

Karsono, R., Haryono, S. J., Karsono, B., Harahap, W. A., Pratiwi, Y., & Aryandono, T. (2021). ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer. *BMC Cancer*, *21*(1), 1–7. https://doi.org/10.1186/s12885-021-09083-x

Kementrian Kesehatan. (2015). Data and Health Information of Cancer Situation. *Igarss 2014*, (1), 1–5. https://doi.org/10.1007/s13398-014-0173-7.2

Kimman, M., Norman, R., Jan, S., Kingston, D., & Woodward, M. (2012). The burden of cancer in member countries of the association of southeast asian nations (ASEAN). *Asian Pacific Journal of Cancer Prevention*, *13*(2), 411–420. https://doi.org/10.7314/APJCP.2012.13.2.411

Kumar, R., Zakharov, M. N., Khan, S. H., Miki, R., Jang, H., Toraldo, G. et al., (2011). The Dynamic Structure of the Estrogen Receptor. *Journal of Amino Acids*, *2011*, 1–7. https://doi.org/10.4061/2011/812540

Kuo, S. H., Yang, S. Y., You, S. L., Lien, H. C., Lin, C. H., Lin, P. H., & Huang, C. S. (2017). Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer. *Oncotarget*, *8*(13), 20925–20938. https://doi.org/10.18632/oncotarget.14995

LaFramboise, T. (2009). Single nucleotide polymorphism arrays: A decade of biological, computational and technological advances. *Nucleic Acids Research*, *37*(13), 4181–4193. https://doi.org/10.1093/nar/gkp552

Lee, Y. H., & Song, G. G. (2013). Un co r re c te d Un co r re c te d. *Neoplasma*, *60*(5), 607–616. https://doi.org/10.4149/neo

Lei, S., Zheng, R., Wang, S., Zhang, S., Shaoming Wang, Ru, C. et al.,(2021). *Global patterns of breast cancer incidence and mortality A population-based cancer registry data analysis from 2000 to 2020* (pp. 41:1183–1194.). pp. 41:1183–1194. https://doi.org/DOI: 10.1002/cac2.12207

Lei Shaoyuan, Zheng, R., Zhang, S., Wang, S., Chen, R., Sun, K. et al., (2021). *Global patterns of breast cancer incidence and mortality A population-based cancer registry data analysis from 2000 to 2020* (pp. 1183–1194). pp. 1183–1194. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.

Li, T., Zhao, J., Yang, J., Ma, X., Dai, Q., Huang, H. et al.,(2016). A meta-analysis of the association between ESR1 genetic variants and the risk of breast cancer. *PLoS ONE*, *11*(4), 1–19. https://doi.org/10.1371/journal.pone.0153314

Liang, J., & Shang, Y. (2013). Estrogen and cancer. *Annual Review of Physiology*, *75*(September 2012), 225–240. https://doi.org/10.1146/annurev-physiol-030212-183708

Lipphardt, M. F., Deryal, M., Fang Ong, M., Schmidt, W., & Mahlknecht, U. (2013). ESR1 single nucleotide polymorphisms predict breast cancer susceptibility in the central European Caucasian population. *International Journal of Clinical and Experimental Medicine*, *6*(4), 282–288.

Ma, H., Lu, Y., Marchbanks, P. A., Folger, S. G., Strom, B. L., McDonald, J. A. et al., (2013). Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women. *Breast Cancer Research*, *15*(5), 1. https://doi.org/10.1186/bcr3486

Marinho, V., Metze, K., SFS, S., Rocha, G., & Gobbi, H. (2008). Molecular features of breast cancer predictive of lymph node metastasesNo Title. *Rev. Assoc. Med. Bras*, *54*(3). https://doi.org/https://doi.org/10.1590/S0104-42302008000300011

Markiewicz, A., Wełnicka-Jaśkiewicz, M., Skokowski, J., Jaśkiewicz, J., Szade, J., Jassem, J., & Zaczek, A. J. (2013). Prognostic Significance of ESR1 Amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 Polymorphisms in Breast Cancer Patients. *PLoS ONE*, *8*(8), 1–10. https://doi.org/10.1371/journal.pone.0072219

Mayr, C. (2019). What are 3′ utrs doing? *Cold Spring Harbor Perspectives in Biology*, Vol. 11. https://doi.org/10.1101/cshperspect.a034728

Muhartono, M., Ramanisa, S., Mutiara, H., & Riduan, R. J. (2016). Hubungan Antara Status Reseptor Estrogen, Reseptor Progesteron Dan Human Epidermal Growth Factor Receptor 2 Dengan Derajat Keganasan Karsinoma Payudara Invasif. *Majalah Kedokteran Andalas*, *39*(2), 65. https://doi.org/10.22338/mka.v39.i2.p65-72.2016

Nagel, A., Szade, J., Iliszko, M., Elzanowska, J., Welnicka-Jaskiewicz, M., Skokowski, J. et al., (2019). Clinical and biological significance of ESR1 gene alteration and estrogen receptors isoforms expression in breast cancer patients. *International Journal of Molecular Sciences*, *20*(8), 1–16. https://doi.org/10.3390/ijms20081881

NIH, & Genetics Home Reference. (2019). ESR1 gene.

Onitilo, A. A., Engel, J. M., Greenlee, R. T., & Mukesh, B. N. (2009). Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. *Clinical Medicine & Research*, *7*(1–2), 4–13. https://doi.org/10.3121/cmr.2009.825

Pandit, P., Patil, R., Palwe, V., Gandhe, S., Patil, R., & Nagarkar, R. (2020). Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional Experience of 2062 Patients. *European Journal of Breast Health*, *16*(1), 39–43. https://doi.org/10.5152/ejbh.2019.4997

Perou, C. M., Sørile, T., Eisen, M. B., Van De Rijn, M., Jeffrey, S. S., Ress, C. A., … Botstein, D. (2000). Molecular portraits of human breast tumours. *Nature*, *406*(6797), 747–752. https://doi.org/10.1038/35021093

Rakha, E. A., Reis-filho, J. S., Baehner, F., Dabbs, D. J., Decker, T., Eusebi, V. et al., (2010). Histological Grade Prognosis. *Breast Cancer Research*, *12*(207), 1–12.

Rayter, 2. (1991). *Steroid receptors in breast cancer*. *78*, 528–535. https://doi.org/DOI: 10.1002/bjs.1800780506

Reinert, T., Saad, E. D., Barrios, C. H., & Bines, J. (2017). Clinical implications of ESR1 mutations in hormone receptor-positive advanced breast cancer. *Frontiers in Oncology*, *7*(MAR), 1–9. https://doi.org/10.3389/fonc.2017.00026

Ripperger, T., Gadzicki, D., Meindl, A., & Schlegelberger, B. (2009). Breast cancer susceptibility: Current knowledge and implications for genetic counselling. *European Journal of Human Genetics*, *17*(6), 722–731. https://doi.org/10.1038/ejhg.2008.212

Romano, S. N., & Gorelick, D. A. (2018). Crosstalk between nuclear and G protein-coupled estrogen receptors. *General and Comparative Endocrinology*, Vol. 261, pp. 190–197. https://doi.org/10.1016/j.ygcen.2017.04.013

Rosen, P. P., Koerner, F. C., Brogi, E., & Hoda, S. A. (2009). *Rosen's Breast Pathology* (Third Edit). Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia.

Ross, D. S., Zehir, A., Brogi, E., Konno, F., Krystel-Whittemore, M., Edelweiss, M. et al., (2019). Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. *Modern Pathology*, *32*(1), 81–87. https://doi.org/10.1038/s41379-018-0116-5

Ruiz-Narváez, E. A., Rosenberg, L., Yao, S., Rotimi, C. N., Cupples, A. L., Bandera, E. V. et al., (2013). Fine-mapping of the 6q25 locus identifies a novel SNP associated with breast cancer risk in African-American women. *Carcinogenesis*, *34*(2), 287–291. https://doi.org/10.1093/carcin/bgs334

Rustamadji, P., & Marisca, S. (2017). Karakteristik Histopatologik dan Imunofenotipik Kanker Payudara di Rumah Sakit Cipto Mangunkusumo Jakarta, Indonesia. *MEDICINUS Vol. 6 No. 3 Juni 2017*, 1–7.

Sa-Nguanraksa, D., Suntiparpluacha, M., Kulprom, A., Kummalue, T., Chuangsuwanich, T., Avirutnan, P., & O-Charoenrat, P. (2016). Association of estrogen receptor alpha and interleukin 6 polymorphisms with lymphovascular invasion, extranodal extension, and lower disease-free survival in thai breast cancer patients. *Asian Pacific Journal of Cancer Prevention*, *17*(6), 2935–2940.

Samavat, H., & Kurzer, M. S. (2015). Estrogen metabolism and breast cancer. *Cancer Letters*, *356*(2), 231–243. https://doi.org/10.1016/j.canlet.2014.04.018

Schettini, F., Buono, G., Cardalesi, C., Desideri, I., De Placido, S., & Del Mastro, L. (2016). Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. *Cancer Treatment Reviews*, *46*, 20–26. https://doi.org/10.1016/j.ctrv.2016.03.012

Schulster, M., Bernie, A. M., & Ramasamy, R. (2016). The role of estradiol in male reproductive function. *Asian Journal of Andrology*, *18*(3), 435–440. https://doi.org/10.4103/1008-682X.173932

Schwabe, J. W. R., & Teichmann, S. A. (2004). Nuclear receptors: the evolution of diversity. *Science's STKE : Signal Transduction Knowledge Environment*, Vol. 2004.

Siddig, A., Mohamed, A. O., Awad, S., Hassan, A. H., Zilahi, E., Al-Haj, M. et al., (2008). Estrogen receptor α gene polymorphism and breast cancer. *Annals of the New York Academy of Sciences*, Vol. 1138, pp. 95–107. https://doi.org/10.1196/annals.1414.015

Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. *CA: A Cancer Journal for Clinicians*, *69*(1), 7–34. https://doi.org/10.3322/caac.21551

Soliman, N. A., & Yussif, S. M. (2016). Ki-67 as a prognostic marker according to breast cancer molecular subtype. *Cancer Biology and Medicine*, *13*(4), 496–504. https://doi.org/10.20892/j.issn.2095-3941.2016.0066

Sommer, S., & Fuqua, S. A. W. (2001). Estrogen receptor and breast cancer. *Seminars in Cancer Biology*, *11*(5), 339–352. https://doi.org/10.1006/scbi.2001.0389

Son, B. H., Kim, M. K., Yun, Y. M., Kim, H. J., Yu, J. H., Ko, B. S. et al., (2015). Genetic polymorphism of ESR1 rs2881766 increases breast cancer risk in Korean women. *J. Cancer Res. Clin. Oncol. 141, 633–645*, *141*, 633–645. https://doi.org/DOI: 10.1007/s00432-014-1849-2

Sugiyono. (2011). *Metode Penelitian Kuantitatif, Kualitatif dan R&D*. Bandung: Afabeta.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, *71*(3), 209–249. https://doi.org/10.3322/caac.21660

Susanti, M., Yustisiana, & Salmi. (2021). Profil Kanker Payudara Di Rsup Dr M Djamil Padang Pada Tahun 2019. *Nusantara Hasana Journal*, *1*(1), 95–101.

Syukri, N. A., Fidiawati, W. A., & Tripriadi, E. S. (2016). Profil Pemeriksaan Indeks Proliferatif Ki-67 Pada Penderita Kanker Payudara Di Rsud Arifin Achmad Tahun 2010-2015. *Jom Fk*, *3*(1).

Tapper, W., Hammond, V., Gerty, S., Ennis, S., Simmonds, P., Collins, A., & Eccles, D. (2008). The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. *Breast Cancer Research*, *10*(6), 1–10. https://doi.org/10.1186/bcr2213

Thomsen, C., Nielsen, S., Nielsen, B. S., Pedersen, S. H., & Vyberg, M. (2019). Estrogen Receptor-α Quantification in Breast Cancer: Concordance between Immunohistochemical Assays and mRNA-In Situ Hybridization for ESR1 Gene. *Applied Immunohistochemistry and Molecular Morphology*, *28*(5), 347–353. https://doi.org/10.1097/PAI.0000000000000760

van der Ploeg, P., van Lieshout, L. A. M., van de Stolpe, A., Bosch, S. L., Lentjes-Beer, M. H. F. M., Bekkers, R. L. M., & Piek, J. M. J. (2021). Functional estrogen receptor signaling pathway activity in high-grade serous ovarian carcinoma as compared to estrogen receptor protein expression by immunohistochemistry. *Cellular Oncology*, *44*(4), 951–957. https://doi.org/10.1007/s13402-021-00600-5

Wang, Y., Waters, J., Leung, M. L., Unruh, A., Roh, W., Shi, X. et al.,(2014). Clonal Evolution in Breast Cancer Revealed by Single Nucleus Genome Sequencing. *PMC*, *512*(7513), 155–160. https://doi.org/10.1038/nature13600

WHO. (2012a). *WHO Classification of Tumour of the Breast. 4th edn.* (4th edn.; R.Lakhani, Ed.). France: International Agency for Research on Cancer (IARC).

WHO. (2012b). *WHO Classification of Tumour of the Breast* (4th ed.; S. R.Lakhani, I. O.Ellis, S. J.Schnitt, P. H. Tan, & M. J. V. de Vijver, Eds.). France: International Agency for Research on Cancer (IARC).

WHO. (2019). *WHO Classification of Tumour; Breast Tumour. 5th Edition.* (5th Editio; Edited by the WHO Classifiction of Tumours Editorial Board, Ed.). Lyon: International Agency for Research on Cancer (IARC).

Widiana, I. K., & Irawan, H. (2020). Clinical and Subtypes of Breast Cancer in Indonesia. *Asian Pacific Journal of Cancer Care*, *5*(4), 281–285. https://doi.org/10.31557/apjcc.2020.5.4.281-285

Wilkins, R. J. (2008). Polygenes, risk prediction, and targeted prevention of breast cancer [1]. *New England Journal of Medicine*, *359*(13), 1406–1407. https://doi.org/10.1056/NEJMc081550

Wu, J., Mamidi, T. K., Zhang, L., & Hicks, C. (2020). Delineation of the Germline and Somatic Mutation Interaction Landscape in Triple-Negative and Non-Triple-Negative Breast Cancer. *International Journal of Genomics*, *2020*. https://doi.org/10.1155/2020/2641370

Yager, J. D., & Davidson, N. E. (2006). Estrogen Carcinogenesis in Breast Cancer. *New England Journal of Medicine*, *354*(3), 270–282. https://doi.org/10.1056/nejmra050776

Yager, J. D., Davidson, N. E., & Hopkins Bloomberg, J. (2006). mechanisms of disease Estrogen Carcinogenesis in Breast Cancer. *N Engl J Med*, *354*, 270–282. Retrieved from www.nejm.org

Yaşar, P., Ayaz, G., User, S. D., Güpür, G., & Muyan, M. (2017). Molecular mechanism of estrogen–estrogen receptor signaling. *Reproductive Medicine and Biology*, *16*(1), 4–20. https://doi.org/10.1002/rmb2.12006

Yeger, J. D., & Davidson, N. E. (2006). Estrogen Carcinogenesis in Breast Cancer. *Endocrinology and Metabolism Clinics of North America*, *40*(3), 473–484. https://doi.org/10.1016/j.ecl.2011.05.009

Youlden, D. R., Cramb, S. M., Yip, C. H., & Baade, P. D. (2014). Incidence and mortality of female breast cancer in the Asia-Pacific region. *Cancer Biology and Medicine*, *11*(2), 101–115. https://doi.org/10.7497/j.issn.2095-3941.2014.02.005

Zhang, Y., Zhang, M., Yuan, X., Zhang, Z., Zhang, P., Chao, H. et al., (2015). Association between ESR1 PvuII, XbaI, and P325P polymorphisms and breast cancer susceptibility: A meta-analysis. *Medical Science Monitor*, *21*, 2986–2996. https://doi.org/10.12659/MSM.894010

Zundelevich, A., Dadiani, M., Kahana-Edwin, S., Itay, A., Sella, T., Gadot, M. et al., (2020). Erratum: ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis (Breast Cancer Research (2020) 22:16 DOI: 10.1186/s13058-020-1246-5). *Breast Cancer Research*, *22*(1), 1–11. https://doi.org/10.1186/s13058-020-01265-y